Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

0(0%)

Results Posted

20%(1 trials)

Phase Distribution

Ph phase_2

20%

Ph phase_1

80%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

4(80.0%)

Phase 2Efficacy & side effects

1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 14 (80.0%)

Phase 21 (20.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_2

A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

NCT05563246

completedphase_1

Clinical Trials (5)

Showing 5 of 5 trials

NCT05563246Phase 2

A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

Completed

NCT05778864Phase 1

A Study of LY3473329 in Participants With Impaired and Normal Renal Function

Completed

NCT06342596Phase 1

A Study of Carbon-14-Labelled [14C] LY3473329 in Healthy Male Participants

Completed

NCT05038787Phase 1

A Study of LY3473329 in Healthy Japanese Participants

Completed

NCT04472676Phase 1

A Study of LY3473329 in Healthy Participants

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5